[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Fundamental and clinical studies on imipenem/cilastatin sodium (MK-0787/MK-0791) were carried out and the results obtained were summarized below. The transfer of MK-0787/MK-0791 into female genital organ tissues was found to be satisfactory. The transfer of MK-0787/MK-0791 into umbilical arterial blood, umbilical venous blood and amniotic fluid was relatively good. A dose of 1,000 mg/1,000 mg per day of MK-0787/MK-0791 was given to each of 6 gynecology patients for 5-22 days and satisfactory clinical effect was obtained in 5 patients out of 6 patients. No notable side effects or abnormal laboratory findings were observed except for a moderate in elevation in S-GOT/S-GPT in 1 case.
Hatase
T
T
Kawano
K
K
Fukagawa
R
R
Hirai
H
H
Ohokura
N
N
Akagi
T
T
Tsunawaki
A
A
Kato
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D015377:Cilastatin; D003521:Cyclopropanes / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D015378:Imipenem; D008431:Maternal-Fetal Exchange; D008875:Middle Aged; D011247:Pregnancy; D013845:Thienamycins / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases